TG Therapeutics, Inc. (TGTX) Q3 2026 earnings results
TG Therapeutics, Inc. (TGTX) reported Q3 2026 results on Nov 9, 2026, 7:04:06 AM ET: GAAP EPS $0.35 vs. $0.26 expected (beat by 35.9%); revenue $259.94M vs. $245.45M expected (beat by 5.9%). Outlook: Full-year 2026 total global revenue guidance raised to approximately $1 billion.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (GAAP, diluted) | $0.35 | $0.26 | Beat by 35.9% |
| Revenue | $259.94M | $245.45M | Beat by 5.9% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 9, 2026, 7:04:06 AM ET. Nexqual published them 39 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 60.7% from $161.71M; GAAP diluted EPS was $0.35 vs. $2.43 (−85.6%).
Stock reaction
The results came out before the market opened. TGTX closed at $63.38 on November 9, 2026, up 5.9% from its $59.83 close on November 6, 2026 before the results. Latest: $65.89 as of 11:32 AM ET, +10.1% since the pre-release close.
Questions and answers
Did TG Therapeutics, Inc. beat earnings expectations?
Yes. TG Therapeutics, Inc. reported GAAP EPS of $0.35 against an average analyst estimate of $0.26 (beat by 35.9%), and revenue of $259.94M against $245.45M expected (beat by 5.9%).
What were TG Therapeutics, Inc.'s Q3 2026 earnings and revenue?
GAAP diluted EPS of $0.35 and revenue of $259.94M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 60.7% from $161.71M; GAAP diluted EPS was $0.35 vs. $2.43 (−85.6%).
When did TG Therapeutics, Inc. report Q3 2026 earnings?
Nov 9, 2026, 7:04:06 AM ET, in an SEC 8-K filing (Item 2.02).
How did TGTX stock react to the earnings?
The results came out before the market opened. TGTX closed at $63.38 on November 9, 2026, up 5.9% from its $59.83 close on November 6, 2026 before the results. Latest: $65.89 as of 11:32 AM ET, +10.1% since the pre-release close.
What did TG Therapeutics, Inc. say about its outlook?
Full-year 2026 total global revenue guidance raised to approximately $1 billion.
More on TGTX
TGTX stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 9, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:32 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:32 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt